NapaJen Pharma Closes $12.4M Series C Financing

healthcareNapaJen Pharma, Inc., a Burlingame, CA-based biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents, closed a $12.4m Series C financing.

The round was led by the existing investor, INCJ, Ltd., with participation from existing investor Mitsui & Co. Global Investment and newly participating P&E Directions Inc.

The funding will be used to complete the Phase 1 clinical development of NJA-730 started in the autumn of 2018 in Australia and prepare for further development.

Founded in 2004, NapaJen Pharma is a clinical-stage biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents. NapaJen has developed a proprietary platform technology in which oligonucleotide compounds are stably and selectively delivered to immune cells.
NJA-730 is a novel immunosuppressive therapeutic agent that combines an anti-CD40 small interfering RNA (siRNA) with the company’s beta-glucan delivery technology. The primary objective of the study is to evaluate the safety and tolerability of NJA-730 administered intravenously. Key secondary objectives will include an assessment of the pharmacokinetic profile of the compound. Investigators will also evaluate the impact of NJA-730 on CD40 gene suppression.

FinSMEs

09/01/2019

Join the discussion